The purpose of this study is to collect information of the clinical course of patients with COVID-19 treated at Tokushukai hospitals with and without antiviral drugs and to explore the clinical course in the acute phase, the frequency of severe disease, and frequency of post COVID-19 condition by the treatment, after adjusting by patient background including risk factor(s) and symptoms at the time of registration.
Conditions
Interventions
None listed
Sponsors
Shionogi & Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria are eligible. 1)Patients with SARS-CoV-2 infection with symptoms and diagnosed as COVID-19 at Tokushukai Hospitals 2)Patients within 5 days from the date of COVID-19 onset to the date of consent 3)Patients who have given informed consent/assent in writing of their own free will to participate in this study (including their parental consent in case of patients are under 18 years of age at the time of consent) 4)Male and Female aged 12 years or older at the time of informed consent
Exclusion criteria
Exclusion criteria: Patients who meet at least one of the following criteria are excluded. 1) Patients who received anti-SARS-Cov-2 drugs within 30 days prior to registration. 2) Patients who have previously participated in this study. 3) Patients who are currently participating in a clinical trial or an interventional prospective study. (Excluding minor interventions) 4) Patients who have not passed 150 days since the last dose of investigational study drug or unapproved drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All patients Subject background Adherence of anti SARS CoV2 drug Incidence of post COVID 19 condition Incidence of severe disease Frequency of hospital re visit for COVID 19 Administration of antimicrobial agents Change from baseline in work productivity score Change in score of support and care required Adverse events of anti SARS CoV 2 drugs Inpatients only Time to alleviation of each COVID 19 symptom Time to alleviation of COVID 19 symptoms (all 14 symptoms) Time to resolution of fever | — |
Countries
Japan
Contacts
Public ContactMasahiro Kinoshita
Shionogi & Co., Ltd. Medical Affairs
Outcome results
None listed